Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia
about
Pediatric AML: From Biology to Clinical ManagementFeasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia.Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin.Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.Novel agents for the treatment of childhood acute leukemia.Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy.Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies.CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.Molecular therapeutic approaches for pediatric acute myeloid leukemia.Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.Gemtuzumab ozogamicin in acute myeloid leukemia.Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials.Minimal Residual Disease in Acute Myeloid Leukemia.Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531.Advances in immunotherapy for pediatric acute myeloid leukemia.Recent research and future prospects for gemtuzumab ozogamicin: could it make a comeback?Piperlongumine induces apoptosis and autophagy in leukemic cells through targeting the PI3K/Akt/mTOR and p38 signaling pathways.Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells
P2860
Q26799773-9E2DB46C-6A51-4DC7-A4B9-267E73406B2FQ33779342-182FDA76-9CF8-4C2E-884B-CB6160AABB8AQ34172042-B31DBD9F-D85E-41EF-9F81-DB1271C5E357Q34227693-31B833A6-6A4D-41FF-95D9-859F7B9E02B6Q34380489-66526E52-E42C-4DF3-86BF-FDE666B329CCQ35192790-666544DB-1934-4131-9D44-BFE8BD133035Q36261159-894CA85D-A5C1-4DFF-B9D9-B2250525E95FQ36386891-C2636B6B-C30C-4368-8D02-62430ACBC117Q36914445-A1C22262-FFE9-4CB7-AB30-9E913E156CA0Q37643136-99CDF6BC-C6D7-449A-B18E-1DE21F63D1DFQ38707852-1AA60BD7-B6A9-4E1E-8620-4F68B3C8B495Q38728718-2357C7C9-370E-4766-9006-C5E14962D6B3Q38757036-B153D56B-1F03-4028-918E-4AFA34F820B9Q39097771-2B87EB91-3F3E-49D6-9C5B-BC9B5A74098AQ46278883-0D373C8A-2A8B-4DD5-A3A7-D9E2BFD5F199Q47930962-6502AA49-BA01-4EA9-8E29-858E7F5FBF8DQ48908379-59A4DCFC-A465-4266-A480-48ECDDAC1ADCQ50053840-CBAF8C56-E0A5-4A82-A294-D0A8664E319CQ57174193-5245731E-29A0-47B6-B79D-AAD4BEF85183
P2860
Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Gemtuzumab ozogamicin can redu ...... ildhood acute myeloid leukemia
@ast
Gemtuzumab ozogamicin can redu ...... ildhood acute myeloid leukemia
@en
Gemtuzumab ozogamicin can redu ...... ildhood acute myeloid leukemia
@nl
type
label
Gemtuzumab ozogamicin can redu ...... ildhood acute myeloid leukemia
@ast
Gemtuzumab ozogamicin can redu ...... ildhood acute myeloid leukemia
@en
Gemtuzumab ozogamicin can redu ...... ildhood acute myeloid leukemia
@nl
prefLabel
Gemtuzumab ozogamicin can redu ...... ildhood acute myeloid leukemia
@ast
Gemtuzumab ozogamicin can redu ...... ildhood acute myeloid leukemia
@en
Gemtuzumab ozogamicin can redu ...... ildhood acute myeloid leukemia
@nl
P2093
P2860
P356
P1433
P1476
Gemtuzumab ozogamicin can redu ...... ildhood acute myeloid leukemia
@en
P2093
Carol O'Hear
Ching-Hon Pui
Dario Campana
Elaine Coustan-Smith
Hiroto Inaba
Jeffrey W Taub
Raul C Ribeiro
W Paul Bowman
P2860
P304
P356
10.1002/CNCR.28334
P407
P577
2013-09-04T00:00:00Z